Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Discovery Grants Program - Individual

Laurentian University of Sudbury

$34,000.00

Mechanism and Inhibition of Anthrax Lethal Factor

EF 2016-17

Résumé
Zinc is an essential element, and an indispensable constituent of more than 300 enzymes involved in many critical biological processes. My research program seeks to understand how these enzymes work on the molecular level. Our primary focus of study is the anthrax lethal factor (LF), a zinc-dependent metalloenzyme, which constitutes one of the three components of the anthrax toxin. One of the other components of this toxin is termed protective antigen (PA). PA is a pore-forming protein, which allows LF to enter the host cell cytoplasm where it exerts its deleterious action. The mechanism underlying LF's metalloenzyme activity is still unknown. In addition, a complete picture of how PA mediates the entry of LF into the host cell (a quintessential step for toxicity) is currently lacking. The proposed work is aimed at gaining an understanding of how LF works on the molecular level, and of how interactions between PA and LF lead to the successful transit of the latter protein into the cell. In light of the general concerns regarding anthrax as an animal and human pathogen, as well as a weapon of bioterrorism, the proposed research will provide insights which may be exploited by pharmaceutical enterprises to develop drugs that would counteract the deleterious effects associated with anthrax.
Programme
Discovery Grants Program - Individual
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
312629-2013
Name nom
Siemann, Stefan
Department département
Chemistry and Biochemistry
Organization id
26
Institution établissement
Laurentian University of Sudbury
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2016
Competition year année de concours
2013
Award amount
34000
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
1504
Committee name en
Chemistry
Committee name fr
Chimie
Area of application code
1200
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Advancement of knowledge
Area of application fr
Avancement des connaissances
Research subject code
3603
Research subject group en
Inorganic chemistry
Research subject group fr
Chimie inorganique
Research subject en
Bio-inorganic chemistry
Research subject fr
Chimie bio-inorganique
Partie
4
Nb partie
5
Application title
Mechanism and Inhibition of Anthrax Lethal Factor
Keyword
NSERC
Application summary
Zinc is an essential element, and an indispensable constituent of more than 300 enzymes involved in many critical biological processes. My research program seeks to understand how these enzymes work on the molecular level. Our primary focus of study is the anthrax lethal factor (LF), a zinc-dependent metalloenzyme, which constitutes one of the three components of the anthrax toxin. One of the other components of this toxin is termed protective antigen (PA). PA is a pore-forming protein, which allows LF to enter the host cell cytoplasm where it exerts its deleterious action. The mechanism underlying LF's metalloenzyme activity is still unknown. In addition, a complete picture of how PA mediates the entry of LF into the host cell (a quintessential step for toxicity) is currently lacking. The proposed work is aimed at gaining an understanding of how LF works on the molecular level, and of how interactions between PA and LF lead to the successful transit of the latter protein into the cell. In light of the general concerns regarding anthrax as an animal and human pathogen, as well as a weapon of bioterrorism, the proposed research will provide insights which may be exploited by pharmaceutical enterprises to develop drugs that would counteract the deleterious effects associated with anthrax.